SG11201608441YA - Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect - Google Patents
Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effectInfo
- Publication number
- SG11201608441YA SG11201608441YA SG11201608441YA SG11201608441YA SG11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA SG 11201608441Y A SG11201608441Y A SG 11201608441YA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- salt
- treatment
- pharmaceutical composition
- composition containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014129740 | 2014-06-24 | ||
| JP2015024785 | 2015-02-10 | ||
| PCT/JP2015/068218 WO2015199136A1 (ja) | 2014-06-24 | 2015-06-24 | 新規ピロロピリミジン化合物又はその塩、及びこれを含有する医薬組成物、特にｎａｅ阻害作用に基づく腫瘍等の予防剤及び／又は治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608441YA true SG11201608441YA (en) | 2016-11-29 |
Family
ID=54938214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608441YA SG11201608441YA (en) | 2014-06-24 | 2015-06-24 | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9963456B2 (enExample) |
| EP (1) | EP3103802B1 (enExample) |
| JP (1) | JP6192741B2 (enExample) |
| KR (1) | KR101947289B1 (enExample) |
| CN (1) | CN106661031B (enExample) |
| AU (1) | AU2015281155B9 (enExample) |
| BR (1) | BR112016025835B1 (enExample) |
| CA (1) | CA2946833C (enExample) |
| DK (1) | DK3103802T3 (enExample) |
| ES (1) | ES2656772T3 (enExample) |
| HU (1) | HUE037266T2 (enExample) |
| MX (1) | MX2016015015A (enExample) |
| MY (1) | MY183327A (enExample) |
| NO (1) | NO3103802T3 (enExample) |
| PH (1) | PH12016502130A1 (enExample) |
| PL (1) | PL3103802T3 (enExample) |
| PT (1) | PT3103802T (enExample) |
| RU (1) | RU2658008C2 (enExample) |
| SG (1) | SG11201608441YA (enExample) |
| TW (1) | TWI605048B (enExample) |
| WO (1) | WO2015199136A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI623316B (zh) * | 2015-12-22 | 2018-05-11 | Taiho Pharmaceutical Co Ltd | Antitumor effect enhancer derived from pyrrolopyrimidine compound |
| WO2018085818A1 (en) * | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018085833A2 (en) * | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyl transferase 5 (prmt5) |
| US10865208B2 (en) | 2016-11-11 | 2020-12-15 | Millennium Pharmaceuticals, Inc. | ATG7 inhibitors and the uses thereof |
| JP7125714B2 (ja) * | 2016-12-13 | 2022-08-25 | ヤマサ醤油株式会社 | 抗ウイルス活性を有する２’－デオキシ－７－デアザプリンヌクレオシド誘導体 |
| EP3740491A1 (en) * | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN108822145B (zh) * | 2018-06-11 | 2020-10-23 | 广东工业大学 | 一种磺酰胺类化合物及其制备方法和应用 |
| CN108640945B (zh) * | 2018-06-11 | 2020-10-23 | 广东工业大学 | 一种酰胺类化合物及其制备方法与应用 |
| WO2020014541A2 (en) * | 2018-07-13 | 2020-01-16 | Il-2Rx, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1848718B1 (en) * | 2005-02-04 | 2012-08-01 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| US7989430B2 (en) * | 2005-12-06 | 2011-08-02 | Regents Of The University Of Minnesota | Antibacterial agents |
| MY171289A (en) | 2006-02-02 | 2019-10-07 | Millennium Pharm Inc | Inhibitors of e1 activating enzymes |
| WO2012061551A1 (en) * | 2010-11-05 | 2012-05-10 | Millennium Pharmaceuticals, Inc. | Administration of nedd8-activating enzyme inhibitor |
| JP2014501772A (ja) | 2011-01-07 | 2014-01-23 | レオ ファーマ アクティーゼルスカブ | タンパク質チロシンキナーゼ阻害薬としての新規スルファミドピペラジン誘導体およびその医薬用途 |
| WO2013016906A1 (zh) * | 2011-07-29 | 2013-02-07 | 深圳光启高等理工研究院 | 人工复合材料和人工复合材料天线 |
| PT2657233E (pt) * | 2012-01-19 | 2014-10-24 | Taiho Pharmaceutical Co Ltd | Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal |
-
2015
- 2015-06-24 US US15/122,863 patent/US9963456B2/en active Active
- 2015-06-24 NO NO15811341A patent/NO3103802T3/no unknown
- 2015-06-24 HU HUE15811341A patent/HUE037266T2/hu unknown
- 2015-06-24 KR KR1020177002160A patent/KR101947289B1/ko not_active Expired - Fee Related
- 2015-06-24 BR BR112016025835-5A patent/BR112016025835B1/pt not_active IP Right Cessation
- 2015-06-24 CA CA2946833A patent/CA2946833C/en active Active
- 2015-06-24 JP JP2015555474A patent/JP6192741B2/ja not_active Expired - Fee Related
- 2015-06-24 MY MYPI2016704032A patent/MY183327A/en unknown
- 2015-06-24 EP EP15811341.5A patent/EP3103802B1/en active Active
- 2015-06-24 ES ES15811341.5T patent/ES2656772T3/es active Active
- 2015-06-24 PT PT158113415T patent/PT3103802T/pt unknown
- 2015-06-24 CN CN201580034466.6A patent/CN106661031B/zh not_active Expired - Fee Related
- 2015-06-24 WO PCT/JP2015/068218 patent/WO2015199136A1/ja not_active Ceased
- 2015-06-24 SG SG11201608441YA patent/SG11201608441YA/en unknown
- 2015-06-24 AU AU2015281155A patent/AU2015281155B9/en not_active Ceased
- 2015-06-24 PL PL15811341T patent/PL3103802T3/pl unknown
- 2015-06-24 MX MX2016015015A patent/MX2016015015A/es active IP Right Grant
- 2015-06-24 RU RU2016149319A patent/RU2658008C2/ru active
- 2015-06-24 TW TW104120451A patent/TWI605048B/zh not_active IP Right Cessation
- 2015-06-24 DK DK15811341.5T patent/DK3103802T3/en active
-
2016
- 2016-10-25 PH PH12016502130A patent/PH12016502130A1/en unknown
-
2018
- 2018-02-07 US US15/890,470 patent/US10174040B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| SG11201608441YA (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| IL254722A0 (en) | Indoleamine 3,2-dioxygenase inhibitors for cancer treatment | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| PL3672954T3 (pl) | Związki, ich sole i ich zastosowanie w leczeniu chorób | |
| PL3065732T3 (pl) | Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii | |
| IL263697A (en) | Compounds, preparations and methods for the treatment and/or prevention of cancer | |
| HK1243935A1 (zh) | 有机化合物 | |
| ZA201707951B (en) | Amide compound and use thereof as agent for the treatment and prevention of diseases caused by rna- and/or dna-containing viruses, and concomitant diseases | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| IL263793A (en) | Compounds and preparations for the treatment of cancer | |
| EP3241551A4 (en) | Pharmaceutical composition for treating cancer, containing lactate metal salt | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| EP3148570A4 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| EP3162803A4 (en) | New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient | |
| HK1243936A1 (zh) | 有机化合物 | |
| EP3677267A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF | |
| EP3290051A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
| PL3236961T3 (pl) | Kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu złośliwego | |
| EP3235808A4 (en) | Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same | |
| IL252487B (en) | Arylalkylamine compounds for use in the prevention or treatment of cancer | |
| EP3267992A4 (en) | Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases | |
| EP3219323B8 (en) | Pharmaceutical composition for treatment and/or prevention of hepatitis c | |
| HK1235391A1 (en) | Inhibitors of creatine transport and uses thereof |